Evidence map›Paper›PMID 40103006›Full record

ArticleBMC research notes2025

Genetic analysis of uterine lavage fluids to identify women at high risk of endometrial cancer.

Roman Hrstka, Filip Zavadil-Kokas, Lucie Moukova, Tamara Kolarova, Maryam Shahidianakbar, Milan Anton, Petra Ovesna, Dita Munzova, Marketa Bednarikova, Petra Bretova and 3 more

Abstract read
In one paragraph

Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Roman HrstkaResearch Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, 656 53, Czech Republic. roman.hrstka@mou.cz.
Filip Zavadil-KokasResearch Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, 656 53, Czech Republic.
Lucie MoukovaDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, 656 53, Czech Republic.
Tamara KolarovaResearch Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, 656 53, Czech Republic.
Maryam ShahidianakbarResearch Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, 656 53, Czech Republic.
Milan AntonDepartment of Gynecology and Obstetrics, University Hospital Brno and Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
Petra OvesnaInstitute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
Dita MunzovaDepartment of Gynecology and Obstetrics, University Hospital Brno and Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
Marketa BednarikovaDepartment of Gynecology and Obstetrics, University Hospital Brno and Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
Petra BretovaDepartment of Gynecology and Obstetrics, University Hospital Brno and Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
Lubos MinarDepartment of Gynecology and Obstetrics, University Hospital Brno and Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
Jitka HausnerovaDepartment of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
Vit WeinbergerDepartment of Gynecology and Obstetrics, University Hospital Brno and Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.

Funding

Agentura Pro Zdravotnický Výzkum České Republiky NU21-09-00031European Union and The State Budget of the Czech Republic P JAC; reg. no. CZ.02.01.01/00/22_008/0004644Ministerstvo Školství, Mládeže a Tělovýchovy BBMRI.cz no. LM2023033Ministerstvo Zdravotnictví Ceské Republiky MMCI, 00209805
6 · The paper itself

Abstract

objectivesEndometrial cancer (EC) is the most common malignancy of the female genital tract in developed countries, yet preventive screening remains unavailable, and diagnostic approaches are largely limited to symptomatic women. Despite advancements in precision oncology, the biology of precancerous lesions is less understood compared to advanced disease. To address this gap, we conducted a prospective case-control study analysing uterine lavage fluid from women undergoing diagnostic evaluation. The study included 257 participants: 80 diagnosed with endometrial intraepithelial neoplasia (EIN), 89 with early-stage EC, and 88 healthy controls. Using targeted next-generation sequencing, we examined genetic alterations in 22 selected genes associated with EC development.

resultsOur findings did not confirm a direct association between specific genetic mutations in uterine lavage fluid and the presence of EIN or early-stage EC (p = 0.501). Mutations were detected in both cases and controls, with a higher overall mutation burden observed in controls, suggesting potential background genomic alterations unrelated to EC development. In conclusion, while molecular profiling of uterine lavage fluid remains a promising concept for non-invasive diagnosis, our results highlight significant challenges in specificity. Further studies with larger cohorts and additional biomarkers are necessary to clarify its diagnostic relevance and clinical applicability.

Indexed as

Biomarkers, TumorCarcinoma in SituEndometrial NeoplasmsAdultAgedCase-Control StudiesFemaleHigh-Throughput Nucleotide SequencingHumansMiddle AgedMutationProspective StudiesBiomarkers, TumorDNA sequencingEndometrial cancerEndometrial intraepithelial neoplasiaPrecancer screeningUterine lavage fluids

Identifiers

PMID40103006
PMCPMC11921509

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.